导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -19.99% | 4395/4773 |
| 近一周 | -4.07% | 4992/5465 |
| 近一月 | -3.38% | 2447/5421 |
| 近一季 | -6.00% | 2247/5231 |
| 近半年 | -19.01% | 4322/4920 |
| 近一年 | -25.43% | 4101/4394 |
| 近两年 | 2.69% | 2853/2954 |
| 近三年 | -32.25% | 2224/2253 |
| 成立以来 | -44.22% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-8.98% 4333/4961 |
-11.87% 4355/5312 |
- - |
- - |
| 2025 | 1.96% 3205/4813 |
-5.76% 3314/3635 |
-1.37% 3151/4076 |
20.06% 2041/4524 |
-8.63% 3941/4813 |
| 2024 | -0.52% 2119/3463 |
-8.48% 2232/2808 |
-10.98% 2485/3014 |
32.60% 93/3129 |
-7.91% 2812/3463 |
| 2023 | -25.43% 1975/2656 |
-5.14% 2136/2280 |
-9.32% 2049/2385 |
0.79% 342/2515 |
-13.99% 2475/2655 |
| 2022 | -9.72% 182/2207 |
8.60% 15/1919 |
-9.15% 1903/2016 |
-7.95% 155/2113 |
-0.60% 1627/2208 |
| 2021 | -5.39% 975/1822 |
-1.86% 547/1255 |
-4.82% 1265/1330 |
0.78% 463/1466 |
0.51% 1097/1822 |
| 2020 | -6.97% 983/1250 |
-12.93% 907/1028 |
7.31% 843/1067 |
6.51% 831/1164 |
-6.53% 1142/1184 |
| 2019 | 26.92% 558/1092 |
31.29% 206/739 |
-8.69% 602/788 |
-3.82% 744/850 |
10.07% 167/918 |
| 2018 | -26.42% 383/834 |
- - |
-16.52% 554/631 |
-5.67% 375/660 |
-5.19% 30/682 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 南方中证房地产ETF发起联接A VS. 长安沪深300非周期A(740101) |